SRR33532781
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- G2M_CHECKPOINT+0.500
- WNT_BETA_CATENIN_SIGNALING+0.410
- DNA_REPAIR+0.390
- INTERFERON_ALPHA_RESPONSE+0.360
- MYC_TARGETS_V2+0.360
- MYC_TARGETS_V1+0.260
- INTERFERON_GAMMA_RESPONSE+0.240
- UV_RESPONSE_UP+0.180
- PI3K_AKT_MTOR_SIGNALING+0.170
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- COAGULATION-0.420
- ANGIOGENESIS-0.400
- APICAL_SURFACE-0.320
- ANDROGEN_RESPONSE-0.290
- UV_RESPONSE_DN-0.280
- COMPLEMENT-0.260
- APICAL_JUNCTION-0.250
- MYOGENESIS-0.230
- CHOLESTEROL_HOMEOSTASIS-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518219 | — | E | 0.868 |
| 2 | TCGA-E9-A22G-01A-11R-A157-07 | — | E | 0.849 |
| 3 | TCGA-RS-A6TP-01A-12R-A34R-07 | — | — | 0.839 |
| 4 | SRR33532767 | — | E | 0.838 |
| 5 | SRR650192 | — | — | 0.838 |
| 6 | 20130067.TNBC | — | E | 0.832 |
| 7 | TCGA-66-2757-01A-01R-0851-07 | — | cohortMD1 | 0.820 |
| 8 | TCGA-58-A46M-01A-11R-A24H-07 | — | cohortSQ2 | 0.812 |
| 9 | TCGA-OL-A6VO-01A-12R-A33J-07 | — | E | 0.811 |
| 10 | GSM6454749 | — | F | 0.808 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.410 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.390 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.240 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.180 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.070 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.070 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.020 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |